| Document |
Document Title |
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129041A1 |
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/116714A1 |
Provided in the present application are a compound and the medical use thereof for novel coronavirus pneumonia, which belongs to the technical field of pharmaceuticals. The compound is a compound represented by formula I or formula II, o...
|
|
WO/2022/103960A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/091014A1 |
The present invention relates to an industrial method for the preparation of Benzisothiazolinone formula (I), which is simple, economical, efficient, user and environment friendly, moreover commercially viable with higher yield and chemi...
|
|
WO/2022/070451A1 |
Provided is a composition for treating water that has excellent storage stability as a liquid and high sterilization performance, a water treatment method in which the composition for treating water is used, a method for manufacturing th...
|
|
WO/2022/058965A1 |
Provided herein, inter alia, are compounds of fatty acid glycerol derivatives and compositions including the same.
|
|
WO/2022/051955A1 |
Disclosed is a method for preparing a saccharin compound. Provided is a method for preparing a saccharin compound as shown in formula (1). The method is characterized by comprising the following step: carrying out, in water in the presen...
|
|
WO/2022/008283A1 |
The present invention to a group of compounds of formula (I) useful for the transfer of polyfluoroalkylthiol groups of at least two carbons atoms into a great variety of organic compounds as well as to the process for their preparation. ...
|
|
WO/2020/102100A9 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2021/257849A1 |
Provided are compounds that can find use as nitrosation reagents. Provided are nitrosation methods that include reacting a substrate with one of the provided nitrosation reagents and thereby generating a nitrosation product. Provided are...
|
|
WO/2021/219089A1 |
Provided herein are compounds, pharmaceutical compositions and methods for treating a SARS-CoV-2 infection.
|
|
WO/2021/200178A1 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin in which polarity is increased due to acid activity, and (B) a compound which is represented by a specific general f...
|
|
WO/2021/148934A1 |
The present invention relates to the process of reduction of compound of formula (II) by using a transition metal complex (Z) as a catalyst for hydrogenation reactions to get compound of formula (I). More particularly, the present invent...
|
|
WO/2021/115495A1 |
The present invention relates to a sulfur-containing heterocyclic compound, characterized by: a compound represented by the following structural formula (I) or stereoisomer thereof, a geometric isomer, a tautomer, a racemate, a deuterate...
|
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
|
WO/2021/082997A1 |
An amide compound containing a substituted acetophenone structure fragment, having a structure shown as general formula I. Please see the description for the definitions of substituents in the formula. The compound has a broad-spectrum b...
|
|
WO/2021/055502A9 |
This invention provides a method of ameliorating the symptoms of, or treating a neurodegenerative disorder, Welander distal myopathy, psychiatric illness, or cancer in a mammal, the method comprising administering to the mammal an effect...
|
|
WO/2021/063177A1 |
Use of an insecticide in preventing or killing pests. An active ingredient of the insecticide is an isothiazolinone heterocyclic compound, having the structure formula as represented by formula I or formula II, R1 is hydrogen or alkyl, R...
|
|
WO/2021/059287A1 |
A method of oxygenating a benzylic C-H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze...
|
|
WO/2021/032057A1 |
The invention relates to an agricultural fungicide, the use thereof and a preparation method therefor. The agricultural fungicide has the chemical structure as shown in formula I or formula II. The agricultural fungicide is used for prev...
|
|
WO/2021/000867A1 |
Disclosed are an isoxazoline compound and an application thereof. The structure of the compound is as shown in general formula (I). The definitions of substituents in the formula are described in the description. The description also dis...
|
|
WO/2021/000865A1 |
An isoxazoline compound, a preparation method therefor and an application thereof. The compound has a structured as represented by general formula I. Also provided is use of the compound represented by general formula I as an insecticide...
|
|
WO/2020/255585A1 |
The present invention provides a method for purifying a compound that generates an acid when irradiated with active light or radiation, said method being capable of reducing the content of metal impurities, while having excellent recover...
|
|
WO/2020/254697A1 |
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...
|
|
WO/2020/247701A2 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are ...
|
|
WO/2020/201519A1 |
The present invention is directed to a novel process for purifying a recombinant polypeptide from a solution comprising one or more impurities, wherein the process is a chromatography process which uses saccharin. The present invention a...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/187440A1 |
The invention relates to aqueous benzisothiazoline-3-one-dispersions of sodium-1,2-benzisothiazoline-3-one-particles dispersed in water. The dispersions contain: (a) 15 wt.-% - 35 wt.-% sodium-1,2-benzisothiazoline-3-one and (b) ad. 100 ...
|
|
WO/2020/167893A1 |
The present invention is directed to the administration of a cannabinoid aerosol formulation using a soft mist inhaler (SMI) with reduced cannabinoid-related irritation and/or coughing. Described is an aerosol formulation comprising a ca...
|
|
WO/2020/147739A1 |
The present invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to lysophosphatidic acid receptor antagonists and a preparation method therefor. The compounds of the present invention have high ...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/121667A1 |
An ammonium salt having a saccharin anion, which is represented by formula (1), exhibits excellent thermal stability even though no halogen atom is contained therein. (In the formula, each of R1-R4 independently represents an alkyl group...
|
|
WO/2020/108538A1 |
An RORĪ³ inhibitor having sulfonyl structure, a preparation method thereof, and a pharmaceutical composition containing a plurality of compounds. The inhibitor has a structure represented by formula (I) or formula (V), wherein the compou...
|
|
WO/2020/092906A1 |
Provided herein are co-crystals comprising Compound 1 and a coformer. Pharmaceutical compositions comprising the co-crystals and methods for treating, preventing and managing disease are also disclosed.
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/084059A1 |
The present invention relates to N-nitrosaccharin of the general formula (I), wherein R is either a hydrogen (H) or a nitro group (NO2), its preparation and its use as nitrating agent.
|
|
WO/2020/070181A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and formula (A) are as defined in the description.
|
|
WO/2020/064564A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
|
|
WO/2020/056090A1 |
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...
|
|
WO/2020/040831A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions for increasing glycosylation and treating congenital disorders of glycosylation.
|
|
WO/2020/034945A1 |
The present invention provides a method for preparing a cyclohexane derivative, comprising the following steps: (1) subjecting a compound SM01 and a compound SM02 or a salt thereof to a nucleophilic substitution reaction to obtain a comp...
|
|
WO/2020/034946A1 |
Provided is a method for preparing a cyclohexane derivative, the method comprising the following steps: subjecting a compound, 2-(4-(3,3-dimethylureido)cyclohexyl)acetaldehyde, represented by formula SM01 and a compound represented by fo...
|
|
WO/2020/032813A1 |
New 5-substituted 5-hydrazine-3-methylisothiazole-4-carboxylic acid derivatives with antitumor activity and a method for their preparation have been disclosed. The disclosed compounds inhibit the proliferation of MV 4-11 human bifenotypi...
|
|
WO/2020/002234A1 |
The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD)
|
|
WO/2020/006294A1 |
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
|
|
WO/2019/236890A1 |
The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SA...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
